Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04613596
Title Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mirati Therapeutics Inc.

lung non-small cell carcinoma


Adagrasib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | ITA | ESP | CAN

No variant requirements are available.